Gilman Hill Asset Management LLC Sells 4,498 Shares of Bristol-Myers Squibb (NYSE:BMY)

Gilman Hill Asset Management LLC lessened its stake in shares of Bristol-Myers Squibb (NYSE:BMYGet Rating) by 7.6% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 54,421 shares of the biopharmaceutical company’s stock after selling 4,498 shares during the quarter. Gilman Hill Asset Management LLC’s holdings in Bristol-Myers Squibb were worth $4,190,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of BMY. Mizuho Securities Co. Ltd. grew its position in Bristol-Myers Squibb by 239.0% during the 1st quarter. Mizuho Securities Co. Ltd. now owns 339 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 239 shares during the last quarter. Spectrum Management Group LLC boosted its stake in shares of Bristol-Myers Squibb by 113.1% during the first quarter. Spectrum Management Group LLC now owns 341 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 181 shares during the period. Nauset Wealth Management. LLC bought a new stake in shares of Bristol-Myers Squibb in the first quarter valued at about $27,000. Conrad Siegel Investment Advisors Inc. bought a new position in Bristol-Myers Squibb in the first quarter worth about $28,000. Finally, Evolution Advisers Inc. acquired a new position in shares of Bristol-Myers Squibb during the first quarter valued at about $29,000. Institutional investors own 76.54% of the company’s stock.

Insiders Place Their Bets

In other news, CFO David V. Elkins sold 133,951 shares of the company’s stock in a transaction that occurred on Tuesday, September 13th. The stock was sold at an average price of $71.30, for a total transaction of $9,550,706.30. Following the completion of the sale, the chief financial officer now owns 100,460 shares in the company, valued at $7,162,798. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Bristol-Myers Squibb news, EVP Ann Powell sold 25,000 shares of the stock in a transaction dated Wednesday, September 14th. The stock was sold at an average price of $70.75, for a total transaction of $1,768,750.00. Following the completion of the transaction, the executive vice president now owns 50,476 shares in the company, valued at approximately $3,571,177. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO David V. Elkins sold 133,951 shares of Bristol-Myers Squibb stock in a transaction that occurred on Tuesday, September 13th. The shares were sold at an average price of $71.30, for a total transaction of $9,550,706.30. Following the completion of the sale, the chief financial officer now owns 100,460 shares of the company’s stock, valued at $7,162,798. The disclosure for this sale can be found here. Insiders have sold a total of 233,951 shares of company stock valued at $16,654,206 in the last 90 days. 0.09% of the stock is owned by insiders.

Bristol-Myers Squibb Stock Performance

BMY stock traded down $0.14 during mid-day trading on Friday, hitting $71.15. 136,500 shares of the company were exchanged, compared to its average volume of 10,752,010. The business has a 50 day simple moving average of $72.13 and a 200-day simple moving average of $74.01. The stock has a market capitalization of $151.92 billion, a PE ratio of 23.68, a price-to-earnings-growth ratio of 1.47 and a beta of 0.43. The company has a current ratio of 1.44, a quick ratio of 1.34 and a debt-to-equity ratio of 1.14. Bristol-Myers Squibb has a 1-year low of $53.22 and a 1-year high of $80.59.

Bristol-Myers Squibb (NYSE:BMYGet Rating) last announced its quarterly earnings results on Wednesday, July 27th. The biopharmaceutical company reported $1.93 EPS for the quarter, beating analysts’ consensus estimates of $1.79 by $0.14. The company had revenue of $11.89 billion for the quarter, compared to analysts’ expectations of $11.50 billion. Bristol-Myers Squibb had a net margin of 14.04% and a return on equity of 49.31%. Bristol-Myers Squibb’s revenue was up 1.6% compared to the same quarter last year. During the same period in the prior year, the company posted $1.93 EPS. On average, equities analysts forecast that Bristol-Myers Squibb will post 7.5 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, November 1st. Stockholders of record on Friday, October 7th will be paid a dividend of $0.54 per share. The ex-dividend date of this dividend is Thursday, October 6th. This represents a $2.16 dividend on an annualized basis and a dividend yield of 3.04%. Bristol-Myers Squibb’s payout ratio is 71.76%.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. Bank of America raised their target price on Bristol-Myers Squibb from $78.00 to $80.00 and gave the stock a “buy” rating in a research note on Monday, June 6th. Atlantic Securities upped their price target on Bristol-Myers Squibb from $83.00 to $87.00 and gave the stock an “overweight” rating in a research note on Monday, September 12th. Citigroup reaffirmed a “buy” rating and set a $90.00 price target on shares of Bristol-Myers Squibb in a research note on Friday, June 3rd. Berenberg Bank lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating and cut their target price for the company from $82.00 to $76.00 in a report on Wednesday, September 14th. Finally, BMO Capital Markets lifted their price objective on Bristol-Myers Squibb from $92.00 to $94.00 and gave the company an “outperform” rating in a report on Monday, September 12th. One research analyst has rated the stock with a sell rating, five have given a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Bristol-Myers Squibb currently has a consensus rating of “Moderate Buy” and a consensus price target of $76.36.

Bristol-Myers Squibb Profile

(Get Rating)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis.

Read More

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMYGet Rating).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.